Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 6/2018

01-06-2018 | Systematic Review

A Systematic Review and Meta-Analysis of the Risk of Dementia Associated with Benzodiazepine Use, After Controlling for Protopathic Bias

Authors: Ross Penninkilampi, Guy D. Eslick

Published in: CNS Drugs | Issue 6/2018

Login to get access

Abstract

Background

Benzodiazepine use is highly prevalent in elderly and late middle-aged populations and may be associated with an increased risk of dementia. Observational studies have suggested that benzodiazepine use may increase the risk of dementia, however there have been significant concerns regarding protopathic bias in these studies, precluding conclusive findings.

Objective

The aim of our study was to investigate the risk of dementia associated with the use of benzodiazepines in elderly patients, after controlling for protopathic bias.

Methods

We identified observational studies with more than 50 cases, adequate assessment of benzodiazepine exposure, and reliable dementia diagnosis ascertainment, from the MEDLINE, PubMed, EMBASE, CINAHL, LILACS and CENTRAL electronic databases through to 5 June 2018, with no language limits. The association of any current or former use of short- or long-acting benzodiazepines with incident dementia was analysed. A subgroup analysis was performed by the introduction of lag time to assess the effect of protopathic bias. We also performed analyses considering the effect of higher benzodiazepine cumulative doses and adjustment for psychiatric covariates. Study quality was investigated using the Newcastle–Ottawa Scale.

Results

We identified 15 studies reported in 14 articles, involving 159,090 cases. Ever use of benzodiazepines was associated with a significantly increased risk of dementia [odds ratio (OR) 1.39, 95% confidence interval (CI) 1.21–1.59]. Those studies that implemented the longest lag times of ≥ 5 years, and hence most likely to overcome protopathic bias, found a risk estimate that was marginally attenuated, but still significant (OR 1.30, 95% CI 1.14–1.48). Long-acting benzodiazepines were associated with a marginally higher magnitude risk (OR 1.21, 95% CI 0.99–1.49) than short-acting benzodiazepines (OR 1.13, 95% CI 1.02–1.26), although the former failed to reach statistical significance (p = 0.059).

Conclusions

Our findings indicate that the association between benzodiazepine use and dementia incidence is not purely an artefact due to protopathic bias. Reduction of inappropriate benzodiazepine prescription is likely to attenuate dementia risk.
Appendix
Available only for authorised users
Literature
1.
Seshadri S, Beiser A, Kelly-Hayes M, et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke. 2006;37:345–50.CrossRefPubMed
2.
Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2017;2017(13):325–73.
3.
4.
5.
Billioti de Gage S, Pariente A, Begaud B. Is there really a link between benzodiazepine use and the risk of dementia? Expert Opin Drug Saf. 2015;14:733–47.CrossRefPubMed
6.
Verdoux H, Lagnaoui R, Begaud B. Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med. 2005;35:307–15.CrossRefPubMed
7.
8.
Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72:136–42.CrossRefPubMed
9.
Fastbom J, Forsell Y, Winblad B. Benzodiazepines may have protective effects against Alzheimer disease. Alzheimer Dis Assoc Disord. 1998;12:14–7.CrossRefPubMed
10.
Lagnaoui R, Bégaud B, Moore N, et al. Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol. 2002;55:314–8.CrossRefPubMed
11.
Wu C-S, Wang S-C, Chang I-S, Lin K-M. The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. Am J Geriatr Psychiatry. 2009;17:614–20.CrossRefPubMed
12.
Wu CS, Ting TT, Wang SC, Chang IS, Lin KM. Effect of benzodiazepine discontinuation on dementia risk. Am J Geriatr Psychiatry. 2011;19:151–9.CrossRefPubMed
13.
Imfeld P, Bodmer M, Jick SS, Meier CR. Benzodiazepine use and risk of developing Alzheimer’s disease or vascular dementia: a case-control analysis. Drug Saf. 2015;38:909–19.CrossRefPubMed
14.
Arfè A, Corrao G. The lag-time approach improved drug–outcome association estimates in presence of protopathic bias. J Clin Epidemiol. 2016;78:101–7.CrossRefPubMed
15.
16.
Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health. 2012;66:869–73.CrossRefPubMed
17.
Gomm W, von Holt K, Thome F, et al. Regular benzodiazepine and z-substance use and risk of dementia: an analysis of German claims data. J Alzheimers Dis. 2016;54(2):801–8.CrossRefPubMed
18.
Gray SL, Dublin S, Yu O, et al. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ. 2016;352:i90.CrossRefPubMedPubMedCentral
19.
Bietry FA, Pfeil AM, Reich O, Schwenkglenks M, Meier CR. Benzodiazepine use and risk of developing Alzheimer’s disease: a case-control study bassed on Swiss claims data. CNS Drugs. 2017;31:245–51.CrossRefPubMed
20.
Shash D, Kurth T, Bertrand M, et al. Benzodiazepine, psychotropic medication, and dementia: a population-based cohort study. Alzheimers Dement. 2016;12:604–13.CrossRefPubMed
21.
Chan TT, Leung WC, Li V, et al. Association between high cumulative dose of benzodiazepine in Chinese patients and risk of dementia: a preliminary retrospective case-control study. Psychogeriatrics. 2017;17(5):310–6.CrossRefPubMed
22.
Mawanda F, Wallace RB, McCoy K, Abrams TE. PTSD, psychotropic medication use, and the risk of dementia among US veterans: a retrospective cohort study. J Am Geriatr Soc. 2017;65:1043–50.CrossRefPubMed
23.
Tolppanen AM, Taipale H, Hartikainen S. Head or brain injuries and Alzheimer’s disease: a nested case-control register study. Alzheimers Dement. 2017;13(12):1371–9.CrossRefPubMed
24.
Islam MM, Iqbal U, Walther B, et al. Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology. 2016;47:181–91.CrossRefPubMed
25.
Moher D, Liberati A, Tetzlaff J, Group P. Altman DG Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41.CrossRefPubMed
26.
27.
28.
29.
Orwin RG. A fail-safe N for effect size in meta-analysis. J Edu Stat. 1983;8:157–9.
30.
31.
Chen PL, Lee WJ, Sun WZ, Oyang YJ, Fuh JL. Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study. PLoS One. 2012;7:e49113.CrossRefPubMedPubMedCentral
32.
Cheng K-C, Chen Y-L, Lai S-W, Mou C-H, Tsai P-Y, Sung F-C. Patients with chronic kidney disease are at an elevated risk of dementia: a population-based cohort study in Taiwan. BMC Nephrol. 2012;13:129.CrossRefPubMedPubMedCentral
33.
Hsiao FY, Peng LN, Lin MH, Chen LK. Dose-responsive effect of psychotropic drug use and subsequent dementia: a nationwide propensity score matched case-control study in Taiwan. J Am Med Dir Assoc. 2014;15:509–13.CrossRefPubMed
34.
Shih HI, Lin CC, Tu YF, et al. An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population: a population-based case-control study. Medicine (Baltimore). 2015;94:e809.CrossRefPubMedPubMedCentral
35.
Chiu HY, Lin EY, Wei L, et al. Hypnotics use but not insomnia increased the risk of dementia in traumatic brain injury patients. Eur Neuropsychopharmacol. 2015;25:2271–7.CrossRefPubMed
36.
Lagnaoui R, Tournier M, Moride Y, et al. The risk of cognitive impairment in older community-dwelling women after benzodiazepine use. Age Ageing. 2009;38:226–8.CrossRefPubMed
37.
Saarelainen L, Taipale H, Koponen M, et al. The incidence of benzodiazepine and related drug use in persons with and without Alzheimer’s disease. J Alzheimers Dis. 2016;49:809–18.CrossRefPubMed
38.
Takada M, Fujimoto M, Hosomi K. Association between benzodiazepine use and dementia: data mining of different medical databases. Int J Med Sci. 2016;13:825–34.CrossRefPubMedPubMedCentral
39.
Brodrick JE, Mathys ML. Antidepressant exposure and risk of dementia in older adults with major depressive disorder. J Am Geriatr Soc. 2016;64:2517–21.CrossRefPubMed
40.
41.
Kirkpatrick B, Ross DE. The trap of protopathic bias in neuropsychiatric research. Biol Psychiatry. 1997;41:257–8.CrossRefPubMed
42.
Horwitz RI, Feinstein AR. The problem of “protopathic bias” in case-control studies. Am J Med. 1980;68:255–8.CrossRefPubMed
43.
Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer’s disease: successive emergence of the clinical symptoms. Ann Neurol. 2008;64:492–8.CrossRefPubMed
44.
Bennett S, Thomas AJ. Depression and dementia: cause, consequence or coincidence? Maturitas. 2014;79:184–90.CrossRefPubMed
45.
46.
Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA. 2002;288:1475–83.CrossRefPubMed
47.
Gallagher D, Coen R, Kilroy D, et al. Anxiety and behavioural disturbance as markers of prodromal Alzheimer’s disease in patients with mild cognitive impairment. Int J Geriatr Psychiatry. 2011;26:166–72.CrossRefPubMed
48.
Paterniti S, Dufouil C, Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol. 2002;22:285–93.CrossRefPubMed
49.
Busto UE, Bremner KE, Knight KPT, terBrugge K, Sellers EM. Long-term benzodiazepine therapy does not result in brain abnormalities. J Clin Psychopharmacol. 2000;20:2–6.CrossRefPubMed
50.
Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc. 2002;8:448–60.CrossRefPubMed
51.
52.
Airagnes G, Pelissolo A, Lavallee M, Flament M, Limosin F. Benzodiazepine misuse in the elderly: risk factors, consequences, and management. Curr Psychiatry Rep. 2016;18:89.CrossRefPubMed
53.
Dell’osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry. 2013;28:7–20.
54.
Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use. CNS Drugs. 2004;18:37–48.CrossRefPubMed
55.
Longo LP, Johnson B. Addiction: part I. Benzodiazepines-side effects, abuse risk and alternatives. Am Fam Phys. 2000;61:2121–8.
56.
Gorgels WJ, Oude Voshaar RC, Mol AJ, et al. Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice: a prospective controlled intervention study. Drug Alcohol Depend. 2005;78:49–56.CrossRefPubMed
57.
Kaur S, Mitchell G, Vitetta L, Roberts MS. Interventions that can reduce inappropriate prescribing in the elderly. Drugs Aging. 2009;26:1013–28.CrossRefPubMed
Metadata
Title
A Systematic Review and Meta-Analysis of the Risk of Dementia Associated with Benzodiazepine Use, After Controlling for Protopathic Bias
Authors
Ross Penninkilampi
Guy D. Eslick
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 6/2018
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-018-0535-3

Other articles of this Issue 6/2018

CNS Drugs 6/2018 Go to the issue

Original Research Article

Polypharmacy Among Headache Patients: A Cross-Sectional Study

Review Article

Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview

Review Article

Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors

Correction

Correction to: Gadolinium-Based Contrast Agent-Related Toxicities

Correction

Correction to: Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents

Original Research Article

Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer’s Disease